Akeso, Inc.
Akeso is a listed Chinese biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative medicines. Its work includes monoclonal antibodies, bispecific and multispecific antibodies, and other therapeutic platforms. Cancer and immune-mediated diseases are prominent areas of its research. The company operates an integrated model that connects early discovery with clinical development and commercial production. Its official corporate profile identifies the Hong Kong Stock Exchange listing and describes its technology platforms.
Company at a glance
Corporate information
- Company entity
- Akeso, Inc.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://akesobio.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
HKEX: 09926
bispecific antibodies · antibody therapeutics
oncology · autoimmune disease · metabolic disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Akeso is a listed Chinese biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative medicines. Its work includes monoclonal antibodies, bispecific and multispecific antibodies, and other therapeutic platforms. Cancer and immune-mediated diseases are prominent areas of its research. The company operates an integrated model that connects early discovery with clinical development and commercial production. Its official corporate profile identifies the Hong Kong Stock Exchange listing and describes its technology platforms.
Business, technology & evidence
- SecuritiesHKEX: 09926
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Akeso, Inc. ↗Akeso, Inc. ·
- Official issuer and R&D disclosure · Akeso, Inc. ↗Akeso, Inc. ·
- Official issuer and R&D disclosure · Akeso, Inc. ↗Akeso, Inc. ·
- Official issuer and R&D disclosure · Akeso, Inc. ↗Akeso, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.